NuVasive (NUVA) PT Raised to $72 at Jefferies

Jefferies analyst Raj Denhoy reiterated a Buy rating and lifted his price target on NuVasive (NASDAQ: NUVA) to $72.00 (from $63.00) following results.

Denhoy commented, "NuVasive put up a $2mn/$0.01 rev./EPS beat and raised guidance for the year. The top-line (+8.6% ex-FX, ex-NSO) was driven by continued positive trends in Hardware and Support (which will include Biotronic going forwards) and another very strong quarter for the international business (+33% ex-FX). FY16 sales guidance raised to $962mn and includes $27mn from Biotronic."

The firm raised FY 2016 EPS from $1.48 to $1.65 and FY 2017 EPS from $1.91 to $2.17.

For an analyst ratings summary and ratings history on NuVasive click here. For more ratings news on NuVasive click here.

Shares of NuVasive closed at $62.00 yesterday.

You May Also Be Interested In

• Incyte (INCY) PT Raised to $105 at Truist Securities
• Eledon Pharamceuticals (ELDN) PT Raised to $7 at Leerink
• Progyny (PGNY) PT Raised to $33 at Truist Securities